[长β(2)-肾上腺素能受体激动剂研究进展]。

药学学报 Pub Date : 2016-12-01

Xin-yue Ge, Yong-mei Mo, Li Pan, Mao-sheng Cheng

{"title":"[长β(2)-肾上腺素能受体激动剂研究进展]。","authors":"Xin-yue Ge, Yong-mei Mo, Li Pan, Mao-sheng Cheng","doi":"","DOIUrl":null,"url":null,"abstract":"β2-Adrenoceptor agonists are highly effective bronchodilators and are widely used in the treatment of both chronic obstructive pulmonary disease (COPD) and asthma. In the last 15 years, there has been great interest within the pharmaceutical industry in the discovery of a long β2-adrenoceptor agonist for a mono-therapy or combination therapy. The search for new long-acting β2-adrenoreceptor agonists (LABA’s), for the treatment of asthma and COPD, has become a very active area of drug discovery. This article reviews the mechanisms, potential candidates and research advances of long β2-adrenoceptor agonists.","PeriodicalId":35924,"journal":{"name":"药学学报","volume":"51 12","pages":"1838-44"},"PeriodicalIF":0.0000,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Recent advances in study of long β(2)-adrenoceptor agonist].\",\"authors\":\"Xin-yue Ge, Yong-mei Mo, Li Pan, Mao-sheng Cheng\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"β2-Adrenoceptor agonists are highly effective bronchodilators and are widely used in the treatment of both chronic obstructive pulmonary disease (COPD) and asthma. In the last 15 years, there has been great interest within the pharmaceutical industry in the discovery of a long β2-adrenoceptor agonist for a mono-therapy or combination therapy. The search for new long-acting β2-adrenoreceptor agonists (LABA’s), for the treatment of asthma and COPD, has become a very active area of drug discovery. This article reviews the mechanisms, potential candidates and research advances of long β2-adrenoceptor agonists.\",\"PeriodicalId\":35924,\"journal\":{\"name\":\"药学学报\",\"volume\":\"51 12\",\"pages\":\"1838-44\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"药学学报\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"药学学报","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

β2-肾上腺素能受体激动剂是一种高效的支气管扩张剂，广泛用于慢性阻塞性肺疾病(COPD)和哮喘的治疗。在过去的15年里，制药行业对发现一种用于单一治疗或联合治疗的长β2-肾上腺素能受体激动剂产生了极大的兴趣。寻找新的长效β2-肾上腺素受体激动剂(LABA’s)，用于治疗哮喘和慢性阻塞性肺病，已经成为一个非常活跃的药物发现领域。本文综述了长β2-肾上腺素能受体激动剂的作用机制、候选药物及研究进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

[Recent advances in study of long β(2)-adrenoceptor agonist].

β2-Adrenoceptor agonists are highly effective bronchodilators and are widely used in the treatment of both chronic obstructive pulmonary disease (COPD) and asthma. In the last 15 years, there has been great interest within the pharmaceutical industry in the discovery of a long β2-adrenoceptor agonist for a mono-therapy or combination therapy. The search for new long-acting β2-adrenoreceptor agonists (LABA’s), for the treatment of asthma and COPD, has become a very active area of drug discovery. This article reviews the mechanisms, potential candidates and research advances of long β2-adrenoceptor agonists.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

药学学报 Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

1.20

自引率

0.00%

发文量

期刊介绍： Acta Pharmaceutica Sinica B (APSB) is a bimonthly English peer-reviewed online journal in ScienceDirect, which publishes significant original research articles, communications and high quality reviews of recent advances. APSB encourages submissions from all areas of pharmaceutical sciences, including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics. APSB is a part of the series Acta Pharmaceutica Sinica, which was founded in 1953. The journal is co-published by Elsevier B.V., in association with the Institute of MateriaMedica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.